Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial

OBJECTIVE: To examine the add-on effects, compared to the existing antidiabetes treatment, of the sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and the risk factors of cardiovascular disease (CVD) and chronic kidney disease (CKD) in patients with inadequately controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Masashi, Yamakage, Hajime, Inoue, Takayuki, Odori, Shinji, Kusakabe, Toru, Shimatsu, Akira, Satoh-Asahara, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086326/
https://www.ncbi.nlm.nih.gov/pubmed/32115517
http://dx.doi.org/10.2169/internalmedicine.3473-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086326/
https://www.ncbi.nlm.nih.gov/pubmed/32115517
http://dx.doi.org/10.2169/internalmedicine.3473-19

Ejemplares similares